Keith C. Bible, MD, PhD, medical oncologist, Mayo Clinic, discusses the impact that lenvatinib (Lenvima) has had on the treatment landscape of differentiated thyroid cancer.
Keith C. Bible, MD, PhD
Advertisement
Articles by Keith C. Bible, MD, PhD
Keith C. Bible, MD, PhD, professor of oncology, Mayo Clinic, discusses the promise of pemetrexed and carboplatin as a potential treatment option for patients with follicular cell-derived thyroid cancers.
Advertisement
Latest Updated Articles
Dr. Bible Discusses the Promise of Pemetrexed in Follicular Thyroid CancersPublished: November 1st 2014 | Updated:
Dr. Bible on Impact of Lenvatinib on Treatment Landscape of DTCPublished: February 19th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
4
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
5